TuHURA Biosciences, Inc./NV
A Phase 3 immuno-oncology company developing therapies for immunotherapy resistance.
HURA | US
Overview
Corporate Details
- ISIN(s):
- US49720K1016
- LEI:
- Country:
- United States of America
- Address:
- 10500 UNIVERSITY CENTER DR., 33612 TAMPA
- Website:
- https://tuhurabio.com/
Description
TuHURA Biosciences, Inc. is a Phase 3 clinical-stage immuno-oncology company that develops novel therapeutics to overcome primary and acquired resistance to cancer immunotherapies. The company's pipeline is based on three distinct technology platforms: IMMUNE FX (IFX), an innate immune agonist; TBS-2025; and Bi-Specific Immune Modulating Antibody Drug Conjugates (ADCs). Its lead product candidate, IFX-2.0, is in a Phase 3 registration trial for patients with advanced melanoma who are resistant to checkpoint inhibitors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all TuHURA Biosciences, Inc./NV filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for TuHURA Biosciences, Inc./NV
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for TuHURA Biosciences, Inc./NV via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
